Corundum Neuroscience’s Post

Thanks for your support in basic science to the important field of understanding the brain body links and #neurowellness Corundum Neuroscience

Exciting news in the longevity space! Rejuvenation Technologies Inc., a biotechnology company, announced yesterday a $10.6M seed financing round led by Khosla Ventures. Shanda Ventures, Asymmetry Ventures, Merchant Adventures, Longevitytech.fund, and Y Combinator also participated in the round. The company has also raised $4.6M in grant funding, bringing the total amount raised to $15.2M. Rejuvenation’s co-founders John Ramunas, PhD, CEO, and Glenn Markov, PhD, COO, have worked together for over 12 years, including at Stanford University where they completed their PhDs in the lab of Helen Blau on telomere extension and epigenetic reprogramming. Dan Chambers, thoracic transplant physician and lung fibrosis disease expert from The University of Queensland, will join the company as Chief Medical Officer.   The key role of telomeres and telomerase in cellular aging was recognized with the 2009 Nobel Prize. “There is an immense public interest in aging and in #mRNA due to mRNA-based COVID” vaccines, said Alexander A. Morgan, MD PhD, Partner, Khosla Ventures. Rejuvenation Technologies Inc. is working on developing mRNA-based therapies to address the mechanisms of #aging. Their primary focus is on reversing a key aging mechanism known as #telomere shortening. Telomeres are like biological clocks that shorten as we age, contributing to age-related diseases. Rejuvenation's lead candidate involves delivering optimized telomerase mRNA encapsulated in targeted lipid nanoparticles to reverse telomere shortening in the body. This work is essential because telomere shortening is a fundamental hallmark of aging and plays a role in various age-related problems, including chronic DNA damage, reduced mitochondrial function, cellular senescence, and more. Rejuvenation's technology has shown promise in preclinical models for conditions like liver fibrosis and lung failure, and they believe it could have a broad impact on aging-related diseases. Crucially, their method is made to work quickly, not stay in your body for too long, and be gentle on your immune system, so it doesn't cause problems like making your cells immortal or triggering strong immune reactions. https://lnkd.in/gNQU4s58 #longevity #healthspan #biotechnology #rejuvenation #startup

💸 Latest biotech & pharma fundraising update👇 🤖 Vivodyne closed a $38M seed financing led by Khosla Ventures. Based in Philadelphia, Vivodyne leverages robotic platforms to improve preclinical drug predictions using lab-grown human organs, addressing the challenge of clinical trial unpredictability. 🧠 Alto Neuroscience announced an oversubscribed $45M Series C led by InVivium Capital. Located in Los Altos, Alto aims to pioneer precision psychiatry. Proceeds will further clinical development of ALTO-100 and ALTO-300 for major depressive disorder. ❤️ Supira Medical closed a $40M Series D, led by Cormorant Asset Management, LP and The Capital Partnership. Based in Los Gatos, Supira develops the Supira System, an advanced pVAD aiming at revolutionizing HRPCI and CS patient support, designed to offer full hemodynamic support and real-time pressure measurements. 💊 Reviva Pharmaceuticals raised approximately $30M from registered direct offering. Based in Cupertino, Reviva's mission is to develop therapies for CNS, inflammatory, and cardiometabolic diseases. 🧪 ELEVAI Labs Inc. raised $6M raised from an initial public offering. Based in Newport Beach, Elevai aims to fulfill unmet needs in medical aesthetics using proprietary stem cell exosome tech, focusing on innovative skincare products. Elevai will be listed on the Nasdaq under ticker "ELAB". 🧬 Oryzon Genomics SA Genomics raised 45M Euros from a convertible bond agreement. Based in Madrid and Boston, Oryzon focuses on epigenetics for CNS and oncology, with vafidemstat as a lead product in Phase 2b for Borderline Personality Disorder. #startups #innovation #finance #seriesa #ipo #entrepreneurship #pharma #biotech #biotechnology #fundraising

#Cambridge-based #CeretypeNeuromedicine secures its second round of seed funding. The company’s $2MM funding target was oversubscribed. The round was led by Cedar Street Group, LLC, an early-stage venture and seed financing fund based in #Westchester, NY. Other participants include Leafy Tunnel, The One Mind Accelerator and several private #investors. Ceretype was founded in 2020 by experts in neuromedicine and brain imaging to translate years of academic research into #practical tools that will transform therapeutic #development and clinical care. Since its founding, Ceretype has partnered with several pharmaceutical and biotech companies to help visualize and #quantitatively analyze the impact of their treatments on the #functional networks within patients’ brains. Ceretype has pioneered the practical application & integration of fMRI in neuropsychiatric drug #development and beyond. Their uniquely scalable end-to-end platform makes targeted #biomarkers accessible, delivering actionable evidence to improve drug discovery and, ultimately, #patient care. Ceretype Neuromedicine, Inc. Leafy Tunnel To share your startup story write us on - contact@startuprise.io #ceretypeneuromedicine #funding #startup

As the year wraps up, biotech dominates the week's top 10 announced funding rounds in the US, including: Tome Biosciences: Secured a massive $213M in a Series A and B funding round, unveiling groundbreaking "molecular surgery" technology for gene therapies. Bicara Therapeutics: A familiar face on the list, this Boston-based biotech raised $165M in a Series C round, focusing on developing biologics to combat tumors, with clinical trials already underway for a head and neck cancer treatment. Totus Medicines: Another biotech player, Totus Medicines from California, closed a $66M Series B financing, specialising in small molecule drug discovery and development using covalent libraries and AI tools. Here's to a big 2024 for biotech ⚕ https://lnkd.in/eJUHH2Ev

Startups, what do you see as the greatest challenge in oncology R&D?  This Johnson & Johnson Innovation – JLABS program is designed to equip you with crucial insights, including:   - Establishing proof-of-concept - Navigating clinical trial complexities - Standing out in this competitive field   Access to expertise and resources are key in overcoming challenges in oncology R&D. Join J&J scientists, industry leaders and entrepreneurs as they share how they’ve tackled their most daunting challenges.   Innovators can register here: https://jji.jnj/3v75WzL   #Biotech #startups #oncology #jnjinnovation #innovation #clinicaltrials #research #development #researchanddevelopment #drugdevelopment

Auristone Pte Ltd has recently closed their seed funding round, securing US$4 million with elev8.vc leading the round and participation from SEEDS Capital and Genedant. With an aim to provide better treatment prediction and outcomes for late-stage cancer patients, Auristone is aggregating the largest database of epigenomics data to study extra-cellular gene expressions and generate novel insights not possible in existing genomic tests.  The funds raised will accelerate the development and deployment of Auristone's flagship molecular profiling test, EPI-Call™, which empowers clinicians to tailor treatment plans for late-stage cancer patients based on epigenetic insights. Commenting on the fundraising, Kaixin T., General Manager of SEEDS Capital, said, “Auristone is pushing the envelope in the field of Precision Diagnostics. It has added to the availability and quality of Singapore’s multi-omics data through epigenomics testing and strengthened the industry’s push towards personalised, predictive therapies. SEEDS Capital looks forward to supporting Auristone as it scales into new markets such as South Korea, Japan and beyond. We are excited to partner with the team to further the adoption of epigenomics in genomic testing and create better, personalised healthcare.” Congratulations to Jingming Chew, Eunice Teo and team! #biomedical #healthcare #medtech #funding #venturecapital #startup #fundraising

Engrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, announced the close of an oversubscribed $157 million Series B #financing round. The round was co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn Inc., Ysios Capital, Longwood Fund, Eight Roads Ventures, and existing founding #investor Pivotal Life Sciences. Since its inception in 2019, the Company has raised over $220 million. Engrail Therapeutics is a clinical-stage pharmaceutical company with the aspiration of becoming a leader in #neuroscience. Their purpose is to deliver transformational therapies that improve the lives of patients with neuropsychiatric and neurodevelopmental diseases. Vikram Sudarsan Stacie Weninger Peter Bisgaard To share your startup story write us on - startup@viestories.com #engrailtherapeutics #startup #funding

SFBN Feed: Ikena acquires cancer startup Pionyr after Gilead passes on buyout https://lnkd.in/gd_jhP9C The all-stock deal comes months after Gilead waived an option to buy Pionyr, and gives Ikena some needed breathing room in a tough market. Click here to view original post #BayArea #SanFrancisco #Biotech #Lifescience #News

NextGen Class of 2024: Top Life Sciences Startups to Watch This Year https://lnkd.in/g8EThV8C Seattle-based companies Bonum Therapeutics and Cajal Neuroscience are among BioSpace’s life science startups to watch in 2024. BioSpace’s NextGen Class of 2024 identified this year’s top 30 life sciences companies, over half of which reside in major innovation hubs on the West Coast. Cajal Neuroscience, which is developing a platform to inform discoveries around brain degeneration, ranked 13th  on the list. The company received funding from notable names including Bristol Myers Squibb and Lux Capital. Immune-oncology-focused Bonum Therapeutics came in 16th . The startup launched in November 2022 and received nearly $100 million in Series A funding. The rankings were determined through criteria including potential for growth, innovative efforts, financial support and partnerships. Companies must have launched between September 2022 and September 2023 and received Series A funding to be considered. The post NextGen Class of 2024: Top Life Sciences Startups to Watch This Year appeared first on Life Science Washington . Click here to view original post